Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
Cho, J-H; Lim, J-H; Park, G-Y; Kim, J-S; Kang, Y-J; Kwon, O; Choi, J-Y; Park, S-H; Kim, Y-L; Kim, H-K; Huh, S; Kim, C-D.
Transpl Infect Dis
; 16(2): 295-303, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24628837
[HBsAg clearance rate in patients with HBeAg-positive chronic hepatitis B: a comparative effect analysis based on the real world].
Chronic hepatitis B in children: Therapeutic challenges and perspectives.
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
Hepatitis B virus resistance to antiviral drugs: where are we going?
Mechanisms of hepatitis B virus resistance development.
Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.